Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SALL4 | Q9UJQ4 | 15/20 | 0.81 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20889791 | 0.90 | SALL4 (1.00) | SALL4CDK9TRIM24TRIM33BRD4 | |
| SCHEMBL20889496 | 0.89 | SALL4 (0.79) | SALL4PLAUTRIM24TRIM33GAA | |
| SCHEMBL20889748 | 0.88 | SALL4 (1.00) | SALL4CDK9TRIM24TRIM33BRD4 | |
| SCHEMBL20889542 | 0.83 | SALL4 (0.55) | SALL4CDK9PLAUTRIM33BRD4 | |
| SCHEMBL31193423 | 0.80 | CDK9 (0.76) | SALL4CDK9PLAUTRIM33BRD4 | |
| SCHEMBL20889724 | 0.77 | SALL4 (1.00) | SALL4TRIM24TRIM33GAAMAPT | |
| SCHEMBL20889512 | 0.77 | SALL4 (1.00) | SALL4PLAUTRIM24TRIM33BRD4 | |
| SCHEMBL27075690 | 0.77 | CDK9 (0.56) | SALL4CDK9PLAUTRIM24TRIM33 | |
| SCHEMBL20889554 | 0.76 | CDK9 (0.53) | SALL4CDK9PLAUBRD4GAA | |
| SCHEMBL31193286 | 0.76 | CDK9 (0.55) | SALL4CDK9PLAUTRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| WO-2019070943-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | SALL4, GLI2, TCF4 | SALL4 1/4885CDK9 2218/4885PLAU 2546/4885 |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | SALL4, GLI2, TCF4 | SALL4 1/4885CDK9 2218/4885PLAU 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.